Syntax Bio Partners with Breakthrough T1D for diabetes research

The good news for our Chicago-based portfolio company, Syntax Bio, keeps coming! Syntax receiving an award of up to $856K from Breakthrough T1D to advance a pancreatic beta cell therapy for type 1 diabetes.